137 related articles for article (PubMed ID: 24457229)
1. Insulin-like growth factor-II mRNA-binding protein 3 expression in effusion cytology: a marker for metastatic adenocarcinoma cells and a potential prognostic indicator in gastric adenocarcinoma.
Kim HJ; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2014; 58(2):167-73. PubMed ID: 24457229
[TBL] [Abstract][Full Text] [Related]
2. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks.
Kim NI; Kim GE; Lee JS
Acta Cytol; 2016; 60(3):232-9. PubMed ID: 27387183
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
[TBL] [Abstract][Full Text] [Related]
5. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.
Yuan RH; Wang CC; Chou CC; Chang KJ; Lee PH; Jeng YM
Ann Surg Oncol; 2009 Jun; 16(6):1711-9. PubMed ID: 19357927
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater.
Kim HG; Park MS; Sung JY; Kim YW; Kim HS; Na K
Anticancer Res; 2019 Sep; 39(9):4947-4955. PubMed ID: 31519600
[TBL] [Abstract][Full Text] [Related]
8. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.
Wang L; Li HG; Xia ZS; Lü J; Peng TS
Chin Med J (Engl); 2010 Dec; 123(24):3554-8. PubMed ID: 22166630
[TBL] [Abstract][Full Text] [Related]
9. A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.
Yan J; Wei Q; Jian W; Liu J; Tang H; Ge J; Zhou J; Zhao T
Int J Clin Exp Pathol; 2014; 7(9):5810-8. PubMed ID: 25337222
[TBL] [Abstract][Full Text] [Related]
10. The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma.
Ezzat NE; Tahoun NS; Ismail YM
J Egypt Natl Canc Inst; 2016 Dec; 28(4):229-234. PubMed ID: 27839709
[TBL] [Abstract][Full Text] [Related]
11. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Claudin-4 and EZH2 Immunohistochemistry in Effusion Cytology.
Elhosainy A; Hafez MMA; Yassin EH; Adam M; Elnaggar MS; Aboulhagag NA
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2779-2785. PubMed ID: 36037134
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
15. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
18. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy.
Schmidt MT; Himmelfarb EA; Shafi H; Lin F; Xu H; Wang HL
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):478-87. PubMed ID: 22495381
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.
Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y
Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-II mRNA-binding protein 3 immunocytochemical expression in direct endometrial brushings: Possible diagnostic help in endometrial cytology.
Norimatsu Y; Yanoh K; Maeda Y; Irino S; Hirai Y; Fulciniti F; Kobayashi TK
Cytopathology; 2019 Mar; 30(2):215-222. PubMed ID: 30614088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
